Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Eligibility criteria
Qualifiers
Pathologically proven diagnosis of unresectable or metastatic leiomyosarcoma or adipocytic sarcoma.
Progressed on at least 1 line of prior therapy and have received no more than 4 lines of prior therapy.
Measurable disease per RECIST 1.1.
At least 18 years of age.
Disqualifiers
Pure well-differentiated liposarcoma or low grade leiomyosarcoma.
Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
Prior treatment with zanzalintinib.
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.
Trial design
Treatments tested in this trial
- Zanzalintinib
- Eribulin
Treatment groups
18 Participants
are divided into 3 treatment groupsSponsors and collaborators
Washington University School of Medicine
Lead sponsor
Exelixis
Collaborator
Source ClinicalTrials.gov